Colin D Biggin

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Placeholder
Colin D Biggin
Chief Executive Officer, Managing Director / Clarity Pharmaceuticals

Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Lists and Charts

Total Shareholder Return as at 12/03/26

Rank Company 1 Yr 5 Yr
1000th Clarity Pharmaceuticals 1.41% 0%
1001st Growthpoint Properties Australia 1.06% 0.43%
1002nd Djerriwarrh Investments 1% 4.87%
998th Perpetual Credit Income Trust 2% 8.15%
999th Contact Energy 1.99% 9.2%
View Full List
1675 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

25/11/25
$787.88k Issued
Clarity Pharmaceuticals
20/11/24
$787.88k Issued
Clarity Pharmaceuticals
01/10/24
$990.00k Other
Clarity Pharmaceuticals
Total value as at the date of the transaction
Powered by Morningstar ®

    Related Information

    Access to our data for Colin D Biggin is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Colin D Biggin is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

    To see the data you will need to Subscribe.

    X